Strategy is to first serve India's vaccine needs and then move on to exports, says Adar Poonawalla

Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine development and aims to supply new vaccines globally after meeting India's needs. The investment in Karan Johar's Dharma Productions reflects their broader strategic interests.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L1OIolf
via IFTTT